This "life -saving medicine" finally landed!Someone has been accused of "drug trafficking" ...

November last year,

Ms. Li, a mother of a rare epilepsy child

It is called "drug trafficking" for receiving the closure of chloropasca.

Chopstin is used for

Rare and difficult to cure children with children with children with epilepsy,

It plays a very important role in auxiliary therapy.

However

It is addictive,

Previously, it has not been approved in China.

Source: CCTV News

recent,

Families in children with rare epilepsy ushered in good news!

September 22,

As the original research medicine that urgently need drugs in clinical urgent drugs,

It was also once known as "life -saving medicine"

The first prescription nationwide was opened in the Beijing Union Hospital.

This has made many rare patients and their families see hope.

The Beijing Union Hospital opened the nation's first chloropharazer prescription

In order to meet the patient's demand for a small amount of specific clinical urgently needed drugs that have been listed abroad and have no supply in China, in June of this year, the State Health and Health Bureau and the State Drug Administration jointly formulated and released the "clinical urgent need for temporary imports of drugs for drugs. "And" Cobra Temporary Import Work Plan ".

The "Plan" states that the imports of desertzhan will be implemented one after another at 50 third -level hospitals across the country in Beijing Union Hospital. Children and their families can buy chorica through eligible doctors.

Source: CCTV News

Recently, the Beijing Union Hospital opened the first chlorba cubes in the country. Ms. Mao's son was the first child to use the original drug chinenia after prescribing prescriptions in domestic hospitals.

Ms. Mao's son suffered from baby spasm at the age of two. She has been taking chrysea for nearly 5 years. She has been purchasing from abroad by friends, and often faces the risk of drugs.

Ms. Mao said that if such diseases cannot be taken for a long time, it is easy to repeat and even bring complications.

Time to reduce the approval time of the rare medical medication as much as possible

Zhang Bo, director of the Department of Pharmacy Department of Peking Union Hospital, said that the impact is very serious in terms of children or families. "For example, the impact on the intellectual development of the child, the damage to his body, and the mental stress are very great."

Zhang Bo pointed out that with the import of chloropa occupation of the original drug, the problem of drug use of drugs in domestic refractory epilepsy has been effectively relieved, and it provides a solution for the availability of other rare diseases.

Source: CCTV News

Shao Rong, Executive Dean of the Academy of Pharmaceutical Supervision Science of China Pharmaceutical University, said that the measures to solve the problem of rare disease families mainly include imported original drugs, localization of imported drugs, and imitation.

According to Shao Rong, the registration and approval of imported drugs need to go through multiple strict procedures. In recent years, for rare disease medications, the state drug supervision department also reduces the time of listing approval as much as possible while strictly benefiting the risk benefits. Patients and families saw the dawn as soon as possible.

Shao Rong said that directly imported medicines from abroad, that is, products listed abroad, drug holders are interested in coming to the Chinese market and applying to the drug supervision bureau. Pathopathy, surrounding children's medication, its procedures will be appropriately accelerated.

"It depends on how its clinical data is, whether there are data differentiated data, etc., and also involve the problem of rare disease samples. It depends on the number of samples if there is clinical research? The approval of drugs is relatively flexible under the premise of ensuring safety. "

Domestic drugs are expected to be available in October, and the price is lower than imported drugs

In addition, the first domestic medicine for the treatment of related diseases has been approved recently. Liao Zongquan, deputy director of the enterprise development center, said, "In September, we obtained the" (Drug) Registration Certificate "approved by the State Drug Administration and obtained our production approval. Our company expects this product to be listed in October."

Liao Zongquan revealed that there are relatively few drug audiences used in such rare diseases. There are not many companies engaged in R & D and production in China, and it is not difficult.

"The research and development of psychiatric drugs has more special requirements in the management links. Whether it is materials or actual production, there are some special requirements, such as requiring two people to operate in all aspects."

Regarding the price issue that everyone is concerned about, Liao Zongquan said that the company has not finally determined the sales price, but it can be determined that it will definitely be cheaper than imported drugs.

We look forward to it together!

Source: CCTV Comprehensive CCTV News, Elephant News, Surging News

- END -